- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Blue Jet Healthcare has reported impressive financial results for Q3 FY25, with a record PAT of Rs. 990 million, marking a 208.3% YoY increase. Revenue from operations surged by 90.9% to Rs. 3,184 million, primarily driven by robust demand in Pharmaceutical Intermediates. EBITDA also saw strong growth, reaching Rs. 1,240 million, up 127.2% YoY, leading to an EBITDA margin of 39%, an increase of 630 bps YoY.
The company recently commissioned an additional manufacturing block in Ambernath, aimed at enhancing production capabilities. For the nine months ended December 31, 2024, the company reported a PAT of Rs. 1,951 million, a 57.2% increase from the previous year. With strong liquidity of Rs. 3,313 million, Blue Jet Healthcare is well-positioned for sustained growth. The outlook remains positive as the company continues to invest in expanding its operational capacities and developing advanced pharmaceutical products.